TRACON Pharmaceuticals Inc (NASDAQ:TCON) shares traded -12.45% lower at $0.17 on Wall Street last session.
TCON stock price is now -37.43% away from the 50-day moving average and -28.07% away from the 200-day moving average. The market capitalization of the company currently stands at $7.65M.
With the price target maintained at $14, BTIG Research recently Upgraded its rating from Neutral to Buy for TRACON Pharmaceuticals Inc (NASDAQ: TCON). On February 10, 2021, Maxim Group recently initiated its ‘Buy’ rating on the stock quoting a target price of $24, while ‘H.C. Wainwright’ rates the stock as ‘Buy’
In other news, THEUER CHARLES, President and CEO bought 47,000 shares of the company’s stock on Apr 27 ’23. The stock was bought for $35,250 at an average price of $0.75. Upon completion of the transaction, the President and CEO now directly owns 399,417 shares in the company, valued at $67900.89. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 26 ’23, President and CEO THEUER CHARLES bought 3,999 shares of the business’s stock. A total of $2,639 was incurred on buying the stock at an average price of $0.66. This leaves the insider owning 352,417 shares of the company worth $59910.89. A total of 11.53% of the company’s stock is owned by insiders.
During the past 12 months, TRACON Pharmaceuticals Inc has had a low of $0.13 and a high of $2.14. The fifty day moving average price for TCON is $5.4369 and a two-hundred day moving average price translates $4.5757 for the stock.
The latest earnings results from TRACON Pharmaceuticals Inc (NASDAQ: TCON) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at $0.01, beating analysts’ expectations of -$0.08 by 0.09. This compares to -$0.30 EPS in the same period last year.
TRACON Pharmaceuticals Inc(TCON) Company Profile
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company’s clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
